Version of 20.04.

2020
Overview of planned and ongoing clinical studies of vaccines for COVID-19

Vaccine, Sponsor Study identifier/link Location Study design Primary outcome Status of trial Importance
to website
Sponsor: National NCT04283461 United States, Phase 1 open label dose ranging Relevant safety outcomes; Recruiting High
institute of Allergy and Washington study of the safety and 12 months follow-up
Infectious diseases; immunogenicity of 2019 nCoV Estimated study
vaccine (mRNA1273) in healthy adults completion: June 2021
Moderna Therapeutics;
N=45, 3 arm study
25 mcg, 100 mcg, 250 mcg
Recombinant Novel ChiCTR2000030906 Hubei, China A single-center, open and dose- Adverse reactions 7 days post Active, not recruiting High
Coronavirus Vaccine NCT04313127 escalation phase I clinical trial for injection
(Adenovirus Type 5 recombinant novel coronavirus Estimated primary
Vector) (2019-COV) vaccine (adenoviral completion: Dec 30 2020
vector)
Sponsor: CanSino N=108 Healthy adults treated with 3
Biologics Inc. different doses
Ad5-nCoV NCT04341389 China, Hubei A Randomized, Double-blind, Occurrence of adverse Recruiting; High
Insitute of Biotechnology, ChiCTR2000031781 Placebo-controlled Phase II Clinical reactions [ Time Frame: 0-14 Estimated Primary
Academy of Military Trial to Evaluate the Safety and days post vaccination ] Completion: January 31,
Medical Sciences, PLA of Immunogenicity of the Recombinant Anti SARS-CoV-2 S antibody 2021
China Novel Coronavirus Vaccine response(ELISA) [ Time Frame:
(Adenovirus Vector) in Healthy Adults 28 days post vaccination ]
CanSino Biologics Inc. Aged Above 18 Years Neutralizing antibody response
N=500 healthy individuals to SARS-CoV-2 [ Time Frame:
randomised to 28 days post vaccination ]
1×10^11vp of Ad5-nCoV
5×10^10vp of Ad5-nCoV
Placebo
Drug: INO-4800 NCT04336410 United States, Missouri Phase 1 Open-label Study to Evaluate Safety and efficacy Not yet recruiting; High
Device: CELLECTRA® 2000 and Pennsylvania the Safety, Tolerability and Time frame week: 28 Estimated Primary
Immunogenicity of INO-4800 for a Completion: November
Sponsor: Inovio Novel Coronavirus (COVID-19) in 2020
Pharmaceuticals Healthy Volunteers

N=40
Two different doses will be tested
bacTRL-Spike NCT04334980 Canada, British A Phase 1, Randomized, Observer- Frequency of Adverse Events Not yet recruiting; High
Columbia Blind, Placebo-Controlled Trial to Estimated Primary
Sponsor: Symvivo Canada, Nova Scotia Evaluate the Safety, Tolerability and Each participant will remain in Completion Date : August
Corporation Immunogenicity of the bacTRL-Spike the trial for 12-13 month 31, 2021
Oral Candidate Vaccine for the
Prevention of COVID-19 in Healthy
Adults
N=84
3 different doses will be tested
 Version of 20.04.2020
BCG Vaccine NCT04327206 Murdoch Children’s Randomised, multi-center clinical trial TBD Recruiting; High
Early news: Research Institute in to test the use of BCG vaccine against
Licensed for tuberculosis Australia COVID-19 patients BCG will be assessed for its Estimated primary
The BRACE trial ability to mitigate the completion: October 30,
Will include 4.170 healthcare workers prevalence and severity of 2020
https://www.mcri.ed across AU, incl Melbourne Campus’ COVID-19 symptoms.
u.au/BRACE Royal Children’s Hospital

https://www.clinicalt
rialsarena.com/news
/australia-bcg-
vaccine-trial-covid-
19/
BCG vaccine EudraCT: 2020- Netherlands Randomised placebo controlled Study outcome: “unplanned Ongoing; High
University Medical 000919-69 multi-center clinical trial to test the absenteeism” as it will not be
Center, Netherlands use of BCG vaccine as protection feasible to visit the sick Estimated Primary
NCT04328441 against COVID-19 professionals at home during Completion: October 25,
the coronavirus pandemic 2020
https://www.science Will include 1.000 healthcare workers
mag.org/news/2020/ across 8 Dutch hospitals BCG will be assessed for its
03/can-century-old- ability to mitigate the
tb-vaccine-steel- BCG often cause an injection site prevalence and severity of
immune-system- reaction which will unblind the COVID-19 symptoms.
against-new- person receiving BCG, but the
coronavirus researchers will remain blinded.

BCG Vaccine Early news: Germany Phase III, multi-centre clinical trial to Study outcome: Unknown High
VPM1002 http://www.mpiib- test the use of BCG vaccine as BCG will be assessed on
berlin.mpg.de/19900 protection against COVID-19 healthcare workers to see
Licensed for tuberculosis 61/news_publication efficacy of the vaccine as a
_14610776_transferr Likely to begin on 2.000 health-care preventive
ed workers in Germany and soon after in against coronavirus, and on
India as well. elderly patients to check
https://economictim efficacy in reducing clinical
es.indiatimes.com/in severity
dustry/healthcare/bi
otech/pharmaceutica
ls/serum-institute-to-
test-if-tb-vaccine-
vpm1002-is-
effective-against-
covid-
19/articleshow/7480
0246.cms?from=mdr
 Version of 20.04.2020
ChAdOx1 nCoV-19; NCT04324606 UK A Phase I/II Study Number of virologically Not recruiting High
Single-blinded, randomised, placebo confirmed (PCR positive)
University of Oxford http://www.ox.ac.uk controlled, multi-centre study symptomatic cases of COVID- Start:
/news/2020-03-27- N: 510 19 Mar 2020
Based on adenovirus oxford-covid-19- Healthy volunteers aged 18-55
vaccine vector with SARS- vaccine-programme- Occurrence of serious adverse Completion: May 2021
CoV-2 spike protein opens-clinical-trial- events (SAEs) throughout the
recruitment study duration
Intranasal vaccine Early news: USA Phase I estimated to start Q3 2020 TBD Not recruiting; High

Single dose AdCOVID Collaboration Estimated study

between University completion: Unknown
of Alabama at
Birmingham and
Altimune Inc.

https://www.drugtar
getreview.com/news
/59182/biotech-and-
academia-
collaborate-on-
intranasal-covid-19-
vaccine-
development/
LV-SMENP vaccine. NCT04276896 China, Guangdong Phase 1 and phase 2 Clinical improvement based on Recruiting; High
Modification of dendritic the 7-point scale [Time Frame:
cells and activate T cells Multicenter Trial of Lentiviral 28 days after randomization] Estimated primary
Sponsor: Minigene Vaccine (LV-SMENP) of completion/estimated
Shenzhen Geno-Immune Covid-19 Lower Murray lung injury score primary completion: July
Medical Institute [Time Frame: 7 days after 31, 2023/ Dec 31, 2024
N=100 with confirmed covid-19 randomization]
Covid-19/aAPC vaccine: NCT04299724 China, Guangdong Phase 1, open label single group Frequency of vaccine events Recruiting High
Pathogen-specific antigen assignment and frequency of serious Estimated primary
presenting cells (APC). N=100, Healthy and Covid-19-positive vaccine events [ Time Frame: completion/estimated
Modify artificial APC volunteers Measured from Day 0 through primary completion: July
(aAPC) and to activate T Day 28]; 31, 2023/ Dec 31, 2024
cells. Proportion of subjects with
Sponsor: Shenzhen positive T cell response [ Time
Geno-Immune Medical Frame: 14 and 28 days after
Institute randomization]
Inactivated ChiCTR2000030016 Guangxi Zhuang, China N=60 with viral negative-transforming Recruiting Medium
mycobacterium vaccine Covid-19 randomized to vaccine or time;30-day cause-specific
Sponsor: Guangxi medical http://www.chictr.or ??? mortality;30-day cause-adverse Dec 12, 2022
university g.cn/showproj.aspx? events;30-day all-cause
proj=49799 mortality;co-infections;Time
from severe and critical
patients to clinical
improvement;
 Version of 20.04.2020
Sponsor: Shenzhen Third ChiCTR2000030750 China, Shenzhen Phase 1/2 Duration of disease Recruiting Low
People's Hospital Antipyretic rate
Immunotherapy with Severe rate Estimated study
recombinant chimeric DC N=40, 4 arm study completion: Feb 2021
vaccine

Link to WHO’s list of vaccines in preclinical phases, updated April 11, 2020:

https://www.who.int/blueprint/priority-diseases/key-action/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1